Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

8.7%

2 terminated out of 23 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

17%

4 trials in Phase 3/4

Results Transparency

35%

7 of 20 completed with results

Key Signals

7 with results91% success

Data Visualizations

Phase Distribution

21Total

Not Applicable (1)

P 1 (9)

P 2 (7)

P 3 (2)

P 4 (2)

Trial Status

Completed20

Terminated2

Unknown1

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (23)

Showing 20 of 20 trials

NCT05750459Phase 4CompletedPrimary

Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria

NCT05400655Phase 2CompletedPrimary

Anti-malaria MAb in Kenyan Children

NCT07122232Completed

Comparative Study of Thrombocytopenia in Plasmodium Vivax and Falciparum Malaria

NCT05304611Phase 2CompletedPrimary

Anti-malaria MAb in Malian Children

NCT04329104Phase 2CompletedPrimary

Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali

NCT05816330Phase 2CompletedPrimary

L9LS MAb in Malian Adults

NCT03168854Phase 1CompletedPrimary

Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites

NCT03589794Phase 1CompletedPrimary

rCSP/AP10-602 [GLA-LSQ] Vaccine Trial

NCT02497612Phase 2TerminatedPrimary

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

NCT03660839Phase 2CompletedPrimary

Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria

NCT05025761Not ApplicableUnknownPrimary

Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Myanmar

NCT03014258Phase 1CompletedPrimary

A Systems Biology Approach to Malaria Immunity

NCT02773979Phase 1CompletedPrimary

PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States

NCT02996695Phase 1CompletedPrimary

Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults

NCT02663700Phase 1CompletedPrimary

Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso

NCT02780154Phase 1CompletedPrimary

PfSPZ Challenge in Non-immune Adults in Baltimore, USA